ACC infographics are visual representations of important health topics that are intended to provide guidance for clinicians at the point of care. The PDFs can be downloaded for free for easy reference. New infographics are being added to this library continually, so please check back.
For patient-facing infographics, please visit CardioSmart.org/Posters to access the most recent free CardioSmart infographics on several cardiovascular and lifestyle topics.
All infographics should be credited to "American College of Cardiology."
Influence of OTC and Herbal Products on the CV System
Download Image Print [PDF] | Web [.jpg]
Clinically Significant Drug-Drug Interactions With OTC and Herbal Products
Download Image Print [PDF] | Web [.jpg]
Arnett DK, Blumenthal RS, Albert MA, Michos ED et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol. 2019; doi: https://doi.org/10.1016/j/jacc.2019.03.010.
Bowman L, Wallendszus M, Stevens W, Buck G, Barton J, et al (The ASCEND Study Collaborative Group). Effects of aspirin for primary prevention in persons with diabetes mellitus. N Eng J Med. 2018; 379: 1529-1539.
McNeil J, Wolfe R, Woods R,Tonkin A, Donnan G, Nelson M, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Eng J Med. 2018; 379: .1509-1518.
McNeil J, Woods RL, Nelson MR, et al. (ASPREE Investigator Group). Effect of aspirin on disability-free survival in the health elderly. N Eng J Med. 2018; 379: 1499-1508.
McNeil J, Woods RL, Nelson MR, et al. (ASPREE Investigator Group). Effect of aspirin on all-cause mortality in the health elderly. N Eng J Med. 2018; 379: 1519-1528.
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018; 392 (10152): 1036-1046.
1. Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology clinical expert consensus document task force. J Am Coll Cardiol. 2017; 69(7):871-898.
2. Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted Edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Er Heart J. 2019;40:3013-21.
3. Goria R, Dentali F, Crippa M, et al. perioperative Safety and Efficacy of Different Anticoagulation Strategies with Direct Oral Anticoagulants in Pulmonary Vein Isolation: A Meta-Analysis. JACC Clin Electrophysiol 2018;4:794-806.
4. Zhao Y, Lu Y, Qin Y. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation. Int J Cardiol. 2018;270:167-71.
5. Birnie DH, Healey JS, Wells GA, et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J 2018;39:3973-9.
6. Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019;179:1469-1478.
Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J AmColl Cardiol 2010;55:213-20.
Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017;35:893-911. Doi :10.1200/JCO.2016.70.5400
Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 ;104 :1293-1305. Doi :10.1093/jnci/djs317
Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 2020 ;31 :171-190. Doi :10.1016/j.annonc.2019.10.023
Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151-61.
Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. The American Journal of Medicine. 2013;126(3):264-e9.
Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA internal medicine. 2019;179(8):1025-33.
Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. European heart journal. 2011;32(7):820-8.
Veltassa (patiromer) [prescribing information]. Redwood City, CA: Relypsa, Inc; May 2018.
Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clinical Journal of the American Society of Nephrology. 2019;14(6):798-809.
Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. New England Journal of Medicine. 2015;372(3):211-21.
Management of Cardiotoxicity Induced by BTK Inhibitors
Tang CPS, Mcmullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2018;59(7):1554-1564.
Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138–140.
Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 2020 ;31 :171-190. Doi :10.1016/j.annonc.2019.10.023
Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations. Ann Oncol 2020 ;31 :171-190. Doi :10.1016/j.annonc.2019.10.023
Escudier M, Cautela J, Malissen N, et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation. 2017;136(21):2085-2087.
Ball S, Ghosh RK, Wongsaengsak S, et al. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74(13):1714-1727.
Thompson JA. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. J Natl Compr Canc Netw. 2018;16(5S):594-596.
Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019;25:100420.
Influence of OTC and Herbal Products on the CV System
Log in to MyACC
![Web [.jpg]](/-/media/Non-Clinical/Images/Tools-and-Practice-Support/Information-Graphics/2018/10/DOAC-Dosing-for-Atrial-Fibrillation-AFib-Web-UPDATED-Nov-1-2018.jpg?la=en&hash=E161BA970B12E5ECD61A5694E5EA07759764C35E){kind=link}
![Web [.jpg]](/-/media/Non-Clinical/Images/Tools-and-Practice-Support/Information-Graphics/2020/05/W20001-CV-Team-Infographic_jpg.jpg?la=en&hash=AE012D7FF0659CBCEA2DDA9D88D4BA81AF4850E2){kind=link}